FDA Warns that Vancomycin Eye Injections May Lead to Blindness

October 6, 2017: By Joan McKenna

1 Ophthalmic NewsVancomycin injections during eye surgery can lead to hemorrhagic occlusive retinal vasculitis (HORV), a rare, potentially blinding postoperative complication, the FDA warned Oct. 3 in a compounding risk alert to health care providers.

The agency said it received an adverse event report Aug. 14, 2017, for a patient who developed bilateral HORV after being administered injections of a compounded triamcinolone, moxifloxacin, and vancomycin (TMV) formulation in each eye at the conclusion of cataract surgeries performed two weeks apart. The TMV formulation was compounded by Imprimis Pharmaceuticals at its outsourcing facility in Ledgewood, New Jersey.

The FDA said symptoms of HORV include a delayed onset of sudden painless decreased vision, intraocular inflammation, intraretinal hemorrhage, retinal vasculitis, vascular occlusion, and retinal ischemia.

At the 2016 AAO meeting, Dean Eliott, MD, said HORV is suspected to be a rare type III hypersensitivity to vancomycin, but its exact cause and pathogenesis remain unproven.

The FDA said many ophthalmologists use intraocular vancomycin during cataract surgery to prevent postoperative endophthalmitis.

The agency said there is no US-approved vancomycin formulation for intraocular injection, and it is unaware of any adequately controlled studies demonstrating the safety and efficacy of vancomycin in preventing endophthalmitis.

The formulation is usually prepared at the surgical site or obtained in advance of surgery from a compounding pharmacy.

The agency concluded that prophylactic use of vancomycin, alone or in a compounded combination drugs, during cataract surgery is generally not recommended due to the risk of HORV.

The FDA said that, if vancomycin is administered to both eyes, patients with HORV likely will wind up legally blind.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023